SudoScan as a Biomarker of Parkinson's Disease

NACompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

June 30, 2018

Conditions
Parkinson's Disease
Interventions
DEVICE

Sudoscan and clinical assessment

The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.

GENETIC

Skin biopsy

Evaluation of the denervation and synuclein deposition of skin biopsy

All Listed Sponsors
lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT02767037 - SudoScan as a Biomarker of Parkinson's Disease | Biotech Hunter | Biotech Hunter